Myo-inositol in depressive and healthy subjects determined by frontal 1H-magnetic resonance spectroscopy at 1.5 tesla

Journal of Psychiatric Research

Volumn 32, Issue 6, 1998, Pages 411-420

  Frey, R ^a   Metzler, D ^b   Fischer, P ^a   Heiden, A ^a   Scharfetter, J ^a   Moser, E ^b   Kasper, S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

1H magnetic resonance spectroscopy; Antidepressive medication; Depression; Myo inositol

Indexed keywords

ANTIDEPRESSANT AGENT; INOSITOL; PHOSPHATIDYLINOSITOL;

ADULT; AGE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DEPRESSION; FEMALE; FRONTAL LOBE; HUMAN; MALE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SECOND MESSENGER;

ADULT; AGE FACTORS; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; CREATINE; DEPRESSION; FEMALE; FRONTAL LOBE; HUMANS; INOSITOL; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; REPRODUCIBILITY OF RESULTS; SEX FACTORS; STATISTICS, NONPARAMETRIC;

EID: 0032170968     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(98)00033-8     Document Type: Article

References (45)

1. Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie. Hamilton Depression Scale. In: Collegium Internationale Psychiatriae Scalarum, CIPS, editor. Internationale Skalen für Psychiatrie. Weinheim: Beltz Test GmbH, 1986.
2. Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie. In: Das AMDP-System. Göttingen: Hogrefe Verlag, 1995.
3. Baraban JM, Worley PF, Snyder SH. Second messenger systems and psychoactive drug action: focus on the phosphoinositide system and lithium. American Journal of Psychiatry 1989;146:1251-1260.
4. Barkai IA, Dunner DL, Gross HA, Mayo P, Fieve RR. Reduced myoinositol levels in cerebrospinal fluid from patients with affective disorder. Biological Psychiatry 1978;13:65-72.
5. Belmaker RH, Bersudsky Y, Benjamin J, Agam G, Levine J, Kofman O. Manipulation of inositol-linked second messenger systems as a therapeutic strategy in psychiatry. In: Gessa G, Fratta W, Pani L, Serra G, editors. Depression and Mania: From Neurobiology to Treatment. New York: Raven Press, 1995, pp. 67-84.
6. Berridge MJ, Irvine RF. Inositol phosphates and cell signalling. Nature 1989;341:197-205.
7. Brand A, Richter-Landsberg C, Leibfritz D. Metabolism of acetate in rat brain neurons, astrocytes and cocultures: Metabolic interactions between neurons and glia cells, monitored by NMR spectroscopy. Cellular and Molecular Biology 1997;43:645-657.
8. Calker D van, Walden J, Berger M. Effekte von Lithiumionen auf Neurotransmitter und sekundäre Botenstoffe. In: Müller-Oberlinghausen B, Greil W, editors. Die Lithiumtherapie. Berlin, Heidelberg, New York, Tokyo: Springer, 1997, pp. 35-60.
9. Chang L, Ernst T, Poland RE, Jenden DJ. In vivo proton magnetic resonance spectroscopy of the normal aging human brain. Life Sciences 1996;58:2049-2056.
10. Christiansen P, Toft P, Larsson HBW, Stubgaard M, Henriksen O. The concentration of N-acetyl aspartate, creatine+phosphocreatine, and choline in different parts of the brain in adulthood and senium. Magnetic Resonance Imaging 1993;11:799-806.
11. Deicken RF, Fein G, Weiner MW. Abnormal frontal lobe phosphorous metabolism in bipolar disorder. American Journal of Psychiatry 1995;152:915-918.
12. Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Häicke W, Sauter R. Localized high-resolution proton NMR spectroscopy using stimulated echos: initial applications to human brain in vivo. Magnetic Resonance in Medicine 1989a;9:79-93.
13. Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hänicke W, Sauter R. Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites. Magnetic Resonance in Medicine 1989b;11:47-63.
14. Hallcher LM, Shermann WR. The effect of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. Journal of Biological Chemistry 1980;255:10896-10901.
15. Henriksen O. In vivo quantification of metabolite concentrations in the brain by means of proton MRS. NMR in Biomedicine 1995;1:139-148.
16. Hertz L, Wolfson M, Hertz E, Agam G, Richards M, Belmaker RH. Lithium-inositol interactions: Synthesis, uptake, turnover. In: Honig A, van Praag HM, editors. Depression: Neurobiological, Psychopathological and Therapeutic Advances. Chichester, New York, Weinheim, Brisbane, Singapore: John Wiley & Sons, 1997, pp. 519-534.
17. Hurwitz TA, Clark C, Murphy E, Klonoff H, Pate BD. Regional cerebral glucose metabolism in major depressive disorder. Canadian Journal of Psychiatry 1990;35:684-688.
18. Kasper S, Grünwald F, Danos P, Walter H, Klemm E, Brücke T, Podreka I, Biersack HJ. Die Bedeutung der Hirn-SPECT in der Psychiatrie. Der Nuklearmediziner 1994;17:309-326.
19. 31P-MRS. Journal of Affective Disorder 1991;22:185-190.
20. Kato T, Takahashi S, Shioiri T, Inubushi T. Brain phosphorous metabolism in depressive disorders detected by phosphorous-31 magnetic resonance spectroscopy. Journal of Affective Disorder 1992;26:233-230.
21. 7Li magnetic resonance spectroscopy. Journal of Affective Disorder 1993;27:53-60.
22. Kofman O, Belmaker RH. Biochemical, behavioral and clinical studies of the role of inositol in lithium treatment and depression. Biological Psychiatry 1993;34:839-852.
23. Lesser IM, Mena I, Boone KB, Miller BL, Mehringer CM, Wohl M. Reduction of cerebral blood flow in older depressed patients. Archives of General Psychiatry 1994;51:677-686.
24. Levine J, Rapaport A, Lev L, Bersudsky Y, Kofman O, Belmaker RH, Shapiro J, Agam G. Inositol treatment raises CSF inositol levels. Brain Research 1993;627:168-170.
25. Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O, Belmaker RH. Double-blind, controlled trial of inositol treatment of depression. American Journal of Psychiatry 1995;152:792-794.
26. Levine J. Controlled trials of inositol in psychiatry. European Neuropsychopharmacology 1997;7:147-155.
27. Manji HK, Moore GJ, Bebchuk JM. Modulation of brain phosphoinositide signaling by lithium: Relationship to therapeutic response. Biological Psychiatry 1997;42(1)S:290S.
28. Metzler D. Quantitative NMR-Protonenspektroskopie in vivo bei 1,5 tesla und Anwendungsmöglichkeiten bei Stoffwechseluntersuchungen am Gehirn depressiver Patienten. PhD thesis, University of Technology, Vienna (A), 1997.
29. 1H NMR spectra of human brain in vivo. NMR in Biomedicine 1991;4:90-98.
30. Michaelis T, Helms G, Merboldt KD, Hänicke W, Bruhn H, Frahm J. Identification of scyllo-inositol in proton NMR spectra of human brain in vivo. NMR in Biomedicine 1993;6:105-109.
31. Moser E. Clinical proton spectroscopy towards routine diagnostic use. NMR in Biomedicine 1994;7:341-342.
32. 1H MRS Spectrometers. In: Podo F, Bovee WMMJ, de Certaines JD, Henriksen O, Leach MO, Leibfritz D, editors. Eurospin Annual. Rome: Instituto Superiore di Sanita, 1995-1996, pp. 242-254.
33. Mozley PD, Hornig-Rohan M, Woda AM, Kim HH, Alavi A, Payer F, Amsterdam JD. Cerebral HMPAO SPECT in patients with major depression and healthy volunteers. Progress in Neuropsychopharmacology & Biological Psychiatry 1996;20:443-458.
34. Narumi K, Arita M, Kitagawa M, Kumazawa A, Tsumita T. Gas chromatographic analysis of free myo- and scyllo-inositols in animals tissues. Japan Journal of Experimental Medicine 1969;39:399-407.
35. +-inositol cotransporter activity and mRNA levels in brain glia cells. American Journal of Physiology 1992;263:C1282-C1288.
36. Petroff OAC, Spencer DD, Alger JR, Prichard JW. High-field proton magnetic resonance spectroscopy of human cerebrum obtained during surgery for epilepsy. Neurology 1989;39:1197-1202.
37. Pouwels PJW, Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magnetic Resonance in Medicine 1998;39:53-60.
38. Radlbauer R. Localized in vivo MR-Proton-Spectroscopy: Quantification and Applications in Medicine. PhD thesis, University of Technology, Vienna (A), 1994a; pp. 93-102.
39. Radlbauer R, Langenberger KW, Moser E. Qualitätskontrolle für die lokalisierte In-vivo-Protonenspektroskopie an klinischen MR-Geräten. RöFo Fortschritte Röntgenstrahlen 1994b;160:254-259.
40. 1H spectroscopy. Glutamate and glutamine; myo-inositol and related metabolites. NMR in Biomedicine 1991;4:59-63.
41. Shimon H, Agam G, Belmaker RH, Hyde TM, Kleinman JE. Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. American Journal of Psychiatry 1997;154:1148-1150.
42. Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, Ross BD. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 1995;195:65-72.
43. 31P MRS. Biological Psychiatry 1996;40:235-246.
44. Snyder SH. Second messenger and affective illness. Pharmacopsychiatry 1992;25:25-28.
45. Spector R. Myo-inositol transport through the blood-brain barrier. Neurochemical Research 1988;13:785-787.